Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. By two international methods (CLSI and EUCAST)

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 858-863

  Pfaller, Michael A ^a   Messer, Shawn A ^a   Motyl, Mary R ^b   Jones, Ronald N ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal testing; Broth microdilution; Methods comparison

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; MK 3118; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECTROPHOTOMETRY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; GLUCOSYLTRANSFERASES; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS; TRITERPENES;

EID: 84875265220     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks466     Document Type: Article

References (20)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Walker SS, Xu Y, Triantafyllou I et al. Discovery of a novel class of orally active antifungal b-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2011; 55: 5099-106.
3. Peel M, Balkovec J, Fan Wet al. Enfumafungin derivatives: orally active glucan synthase inhibitors. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-845. American Society for Microbiology, Washington, DC, USA.
4. Wilkening R, Apgar J, Meng D et al. Enfumafungin derivatives: orally active glucan synthase inhibitors. In: Abstracts of the Fiftieth Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 2010. Abstract F1-846. American Society for Microbiology, Washington, DC, USA.
5. Andes D, Lepak A, Marchillo K. In vivo pharmacodynamic (PD) target for the oral glucan synthase inhibitor (GSI), MK-3118 (MK) against C. albicans (CA), C. glabrata (CG), and C. parapsilosis (CP) in the neutropenic murine disseminated candidiasis model. In: Abstracts of the Fifty-first Interscience Conference on Antimicobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract A2-579. American Society for Microbiology, Washington, DC, USA.
6. Flattery A, Abruzzo G, Gill C et al. Evaluation of enfumafungin derivative MK-3118 in two mouse models of disseminated aspergillosis. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-849. American Society for Microbiology, Washington, DC, USA.
7. Motyl MR, Tan C, Liberator P et al. MK-3118, an oral enfumafungin with potent in vitro activity against Candida and Aspergillus spp. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-847. American Society for Microbiology, Washington, DC, USA.
8. Flattery A, Abruzzo G, Gill C et al. Evaluation of orally active enfumafungin derivative MK-3118 in mouse models of disseminated candidiasis. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-848. American Society for Microbiology, Washington, DC, USA.
9. Trucksis M, Garrett G, Bautmans A et al. A phase I multiple-rising dose study evaluating safety, tolerability, and pharmacokinetics of MK-3118, oral glucan synthase inhibitor in healthy volunteers. In: Abstracts of the Fifty-first Interscience Conference on Antimicrobioal Agents and Chemotherapy, Chicago, IL, 2011. Abstract F1-1390. American Society for Microbiology, Washington, DC, USA.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
11. Cuenca-Estrella M, Arendrup MC, Chryssanthou E et al. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2007; 13: 1018-22.
12. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
13. Arendrup MC, Garcia-Effron G, Lass-Florl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob Agents Chemother 2010; 54: 426-39.
14. Cuenca-Estrella M, Rodriguez-Tudela JL. The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther 2010; 8: 267-76.
15. Pfaller MA, Castanheira M, Diekema DJ et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010; 48: 1592-9.
16. Pfaller MA, Espinel-Ingroff A, Boyken L et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconzole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011; 49: 845-50.
17. Pfaller MA, Watanabe N, Castanheira M et al. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and EUCAST methods. J Antimicrob Chemother 2011; 66: 2581-4.
18. Pfaller MA, Andes D, Diekema DJ et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-95.
19. Pfaller MA, Castanheira M, Messer SA et al. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011; 69: 45-50.
20. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.